Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).
1 finding from 1 review
Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsh · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Naldemedine showed no clear difference in serious adverse eventsh compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsÂ
Canakinumab showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse eventsÂ
Anakinra showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse eventsk
1 finding from 1 review
Serious adverse eventsl
mRNA‐1273 – ModernaTX showed no clear difference in serious adverse eventsl compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse eventsk
CVnCoV – CureVac AG showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventso
ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in serious adverse eventso compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse eventsg
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in serious adverse eventsg compared with chAdOx1 – University of Oxford (low certainty).
1 finding from 1 review
Serious adverse eventsb
AD26.COV2.S – Janssen Pharmaceutical Companies showed no clear difference in serious adverse eventsb compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse eventsf
Gam‐COVID‐VAC – Sputnik V showed no clear difference in serious adverse eventsf compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsr
CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi
WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsk
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
1 finding from 1 review
Serious adverse eventsi
BBV152 – Bharat Biotech leads to lower serious adverse eventsi compared with placebo (high certainty).
1 finding from 1 review
Serious adverse eventsm
NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with COVID‐19
1 finding from 1 review